Adicet Bio, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Adicet Bio, Inc. (ACET) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $7.02 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- Adicet Bio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $6.85, a 669.66% increase year-over-year.
- Adicet Bio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.89, a 65.90% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $2.61, a 67.62% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $8.06, a 44.76% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $13.76, a 457.09% increase from fiscal 2024.
- Adicet Bio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.47, a 53.92% decline from fiscal 2023.
- Adicet Bio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $5.36, a 63.41% decline from fiscal 2022.
- Adicet Bio, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $14.65, a 1.95% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.02 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $6.85 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $13.76 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $0.86 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $0.87 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $0.89 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $2.47 10-K · filed 2025-03-06 | |||
| 2024-09-30 | $2.48 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $2.53 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $2.61 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $5.36 10-K · filed 2024-03-19 | |||
| 2023-09-30 | $5.48 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $7.53 10-Q · filed 2023-08-09 | |||
| 2023-03-31 | $8.06 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $14.65 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $14.29 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $14.18 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | $14.59 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $14.37 10-K · filed 2022-03-15 | |||
| 2021-09-30 | $14.89 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $15.04 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $15.01 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | $15.14 10-K · filed 2021-03-12 | |||
| 2019-12-31 | $5.39 10-K · filed 2021-03-12 | |||
| 2018-12-31 | $2.26 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |